Farydak

(panobinostat)

ApprovedSmall molecule

Panobinostat is used to treat multiple myeloma, a type of blood cancer. It works by stopping cancer cells from growing and dividing.[2] Farydak is currently approved and in use across 25 indications[4].[1]

Farydak is one of 611 small molecule programs targeting Paraganglioma. It is currently in Approved.

Indications

Total Trials

Active Trials

610

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

ParagangliomaApproved

Diffuse Large B-Cell LymphomaApproved

Non-Hodgkins LymphomaApproved

Soft Tissue SarcomaApproved

HIV InfectionApproved

Type 2 Diabetes MellitusApproved

Neuroendocrine NeoplasmApproved

Thyroid CancerApproved

Hematopoietic and Lymphoid Cell NeoplasmApproved

Graft Versus Host DiseaseApproved

ParagangliomaApproved

Approved

Diffuse Large B-Cell LymphomaApproved

Approved

Non-Hodgkins LymphomaApproved

Approved

Soft Tissue SarcomaApproved

Approved

HIV InfectionApproved

Approved

Type 2 Diabetes MellitusApproved

Approved

Neuroendocrine NeoplasmApproved

Approved

Thyroid CancerApproved

Approved

Hematopoietic and Lymphoid Cell NeoplasmApproved

Approved

Graft Versus Host DiseaseApproved

Approved

Showing 10 of 25 indications

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Farydak

SSecuraBio

Approved

90 2

Sovaldi

Gilead

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Cysteine Hydrochloride

Novartis

Preclinical

1 5

Ibrance

Pfizer

Preclinical

1 6

Coreg

Akero Therapeutics

Preclinical

2 7

Vermox

WWim Janssens

Preclinical

1 8

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 9

Doptelet

AAkarx

Preclinical

1 10

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Sickle Cell Disease

NCT01245179

Q2 2032

ApprovedActive, not recruiting

Primary Myelofibrosis

NCT02386800

Q4 2040

Phase 2Recruiting

Metastatic Colorectal Cancer

NCT05725200

Clinical

Trials by Indication[1]

Multiple Myeloma22 trials

An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma

No longer available· Novartis logo

Novartis··NCT02568943

Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)

Completed·AAjai Chari·Phase 2·NCT01651039·32 enrolled

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01301807·63 enrolled

Show 19 more trials

Panobinostat/Velcade in Multiple Myeloma

Terminated·UUniversity of Arkansas·Phase 1·NCT00891033·12 enrolled

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Completed· Novartis logo

Novartis·Phase 3·NCT01023308·767 enrolled

Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02722941·30 enrolled

Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma

Completed·EEmory University·Phase 1·NCT01549431·32 enrolled

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Terminated·UUniversity of Washington·Phase 2·NCT03256045·9 enrolled

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

Completed·—·Phase 1·NCT01965353·21 enrolled

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

Completed·OOncotherapeutics·Phase 1/2·NCT00743288·40 enrolled

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

Completed· Novartis logo

Novartis·Phase 2·NCT01083602·55 enrolled

MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma

Completed·JJason Valent·Phase 1/2·NCT02057640·16 enrolled

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

Completed·Ppharmaand GmbH·Phase 2·NCT02654990·248 enrolled

Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Withdrawn· Novartis logo

Novartis·Phase 2·NCT02756663

Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma

No longer available· Novartis logo

Novartis··NCT02204553

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01440582·77 enrolled

Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

Completed·MMayo Clinic·Phase 1/2·NCT00918333·124 enrolled

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Completed·—·Phase 1·NCT00962507·11 enrolled

Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma

Unknown status·PProf Jamie Cavenagh·Phase 1/2·NCT02145715·54 enrolled

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

Completed·SSCRI Development Innovations, LLC·Phase 1/2·NCT01496118·80 enrolled

Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

Withdrawn·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT02802163

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02506959·83 enrolled

Lymphoma8 trials

Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma

Unknown status·—·Phase 1·NCT01884428·24 enrolled

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Completed· Novartis logo

Novartis·Phase 2·NCT00742027·129 enrolled

Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed·MMayo Clinic·Phase 2·NCT01261247·41 enrolled

Show 5 more trials

Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00967044·31 enrolled

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)

Completed· Novartis logo

Novartis·Phase 3·NCT01034163·41 enrolled

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT01460940·24 enrolled

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT02961816

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01169636·62 enrolled

Breast Cancer5 trials

A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab

Terminated· Novartis logo

Novartis·Phase 1/2·NCT00567879·56 enrolled

Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer

Completed·TTranslational Research in Oncology·Phase 2·NCT00777049·54 enrolled

ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer

Withdrawn·TTulane University Health Sciences Center·Phase 1·NCT00993642

Show 2 more trials

Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer

Terminated·TTranslational Research in Oncology·Phase 2·NCT00777335·4 enrolled

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT01105312·28 enrolled

Myelodysplastic Syndrome3 trials

Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Terminated·SSt. Jude Children's Research Hospital·Phase 1·NCT02676323·19 enrolled

Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Completed·UUniversity of California, San Francisco·Phase 1·NCT01463046·29 enrolled

Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Unknown status·JJohann Wolfgang Goethe University Hospital·Phase 1/2·NCT01451268·62 enrolled

Acute Graft Versus Host Disease2 trials

Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02588339·42 enrolled

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT01111526·22 enrolled

42 more indications

Melanoma2 trials

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02032810·17 enrolled

PDR001 + Panobinostat for Melanoma and NSCLC

Withdrawn·MMuhammad Furqan·Phase 1·NCT03982134

Glioma2 trials

A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT03632317

Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)

Terminated·—·Phase 1·NCT04804709·5 enrolled

Chronic Myelomonocytic Leukemia2 trials

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

Completed· Novartis logo

Novartis·Phase 1·NCT01613976·10 enrolled

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Completed· Novartis logo

Novartis·Phase 1/2·NCT00946647·113 enrolled

Cutaneous T-cell lymphoma2 trials

Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

Terminated· Novartis logo

Novartis·Phase 2·NCT00490776·9 enrolled

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

Completed· Novartis logo

Novartis·Phase 2·NCT00425555·139 enrolled

Primary Myelofibrosis2 trials

A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

Terminated· Novartis logo

Novartis·Phase 2·NCT00931762·35 enrolled

Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies

Active, not recruiting· Novartis logo

Novartis·Approved·NCT02386800·279 enrolled

Prostate Cancer2 trials

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Completed·NNYU Langone Health·Phase 1/2·NCT00878436·52 enrolled

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT00667862·35 enrolled

HIV-12 trials

Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

Completed·MMassachusetts General Hospital·Phase 1/2·NCT02471430·17 enrolled

Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART

Completed·UUniversity of Aarhus·Phase 1/2·NCT01680094·15 enrolled

T-cell acute lymphoblastic leukemia1 trial

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02518750·3 enrolled

Mantle Cell Lymphoma1 trial

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

Completed·AAnand Jillella·Phase 1·NCT01504776·3 enrolled

Surgery1 trial

A Panobinostat Presurgery

Withdrawn·—·Phase 2·NCT01115036

Acute Lymphoblastic Leukemia1 trial

Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Terminated·—·Phase 2·NCT00723203·16 enrolled

Sickle Cell Disease1 trial

Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

Recruiting·AAbdullah Kutlar·Phase 1·NCT01245179·18 enrolled

Small Cell Lung Cancer1 trial

Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Withdrawn·CCancer Trials Ireland·Phase 1·NCT01160731

Adult T-Cell Leukemia/lymphoma1 trial

Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma

Terminated· Novartis logo

Novartis·Phase 2·NCT00699296·4 enrolled

Hematologic Malignancies1 trial

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT01321346·30 enrolled

Trial1 trial

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Treatment1 trial

Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

Completed· Novartis logo

Novartis·Phase 2·NCT01802879·9 enrolled

Acute Myeloblastic Leukaemia1 trial

Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)

Completed·PPETHEMA Foundation·Phase 1/2·NCT00840346·46 enrolled

Malignant Brain Tumors1 trial

Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors

Terminated·NNeurological Surgery, P.C.·Phase 2·NCT00848523·6 enrolled

Pancreatic Cancer1 trial

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01056601·7 enrolled

Myelofibrosis1 trial

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)

Completed·JJohn Mascarenhas·Phase 1/2·NCT01693601·15 enrolled

HSCT1 trial

Panobinostat Maintenance After HSCT fo High-risk AML and MDS

Terminated·GGoethe University·Phase 3·NCT04326764·52 enrolled

Relapsed/Refractory1 trial

Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT

Completed·FFondazione Italiana Linfomi - ETS·Phase 2·NCT01523834·35 enrolled

Patients With Solid Tumors1 trial

A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

Terminated·AAustralian & New Zealand Children's Haematology/Oncology Group·Phase 2·NCT04897880·25 enrolled

Neuroendocrine Tumors1 trial

Study of Panobinostat in Patients With Neuroendocrine Tumors

Terminated·UUniversity of Wisconsin, Madison·Phase 2·NCT00985946·15 enrolled

Gastric Cancer1 trial

Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)

Terminated·TTechnical University of Munich·Phase 2·NCT01528501·28 enrolled

Advanced1 trial

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00738751·44 enrolled

Combination Therapy1 trial

Optimizing Reversal of HIV Latency With Combination Therapy

Unknown status·EErasmus Medical Center·Phase 1/2·NCT06240520·49 enrolled

Solid Tumors1 trial

Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function

Completed· Novartis logo

Novartis·Phase 1·NCT00997399·37 enrolled

Renal Cell Cancer1 trial

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Terminated·RRoswell Park Cancer Institute·Phase 1/2·NCT01582009·26 enrolled

Acute Myeloid Leukemia1 trial

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

Completed· Novartis logo

Novartis·Phase 1·NCT01242774·46 enrolled

Chronic Myelogenous Leukemia1 trial

Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia

Completed·—·Phase 1·NCT00686218·9 enrolled

Stereotactic Radiation1 trial

Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors

Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT01324635·17 enrolled

Liver Cancer1 trial

Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery

Terminated·—·Phase 1·NCT00873002·3 enrolled

Essential Thrombocythemia1 trial

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Completed· Novartis logo

Novartis·Phase 1·NCT01433445·61 enrolled

Myelodysplastic Syndromes1 trial

LBH589 in Refractory Myelodysplastic Syndromes (MDS)

Terminated·SSCRI Development Innovations, LLC·Phase 2·NCT00594230·26 enrolled

Metastatic Colorectal Cancer1 trial

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Recruiting·OOslo University Hospital·Phase 2·NCT05725200·40 enrolled

Malignant Solid Tumors1 trial

Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors

Completed·UUniversity of California, San Francisco·Phase 1·NCT00878904·40 enrolled

Children1 trial

Phase I Study of Marizomib + Panobinostat for Children With DIPG

Terminated·—·Phase 1·NCT04341311·4 enrolled

Esophageal Cancer1 trial

A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer

Completed· Novartis logo

Novartis·Phase 1·NCT00670553·7 enrolled

Colorectal Cancer1 trial

Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy

Terminated·UUniversity of Southern California·Phase 1·NCT01238965·7 enrolled

Unspecified2 trials

Panobinostat Biological Correlates Study

Completed·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT01658241·30 enrolled

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Completed· Novartis logo

Novartis·Phase 1·NCT02890069·298 enrolled

Regulatory

FDA Approval Timeline[5]

Feb 23, 2015

FARYDAK

NDA NDA205353

Sources

References

[1]
ClinicalTrials.gov — 90 trial records for panobinostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Farydak drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — panobinostat compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for panobinostat. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA205353). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Farydak. U.S. Food & Drug Administration.
[7]
SEC EDGAR — SecuraBio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Histone Deacetylase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: SSecuraBio

Patent Landscape[6]

Patent Cliff

Jan 17, 2028

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7989494Jan 17, 2028

8883842Jun 13, 2028

Farydak

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2032

Q4 2040

Trials by Indication[1]

Multiple Myeloma22 trials

Lymphoma8 trials

Breast Cancer5 trials

Myelodysplastic Syndrome3 trials

Acute Graft Versus Host Disease2 trials

Melanoma2 trials

Glioma2 trials

Chronic Myelomonocytic Leukemia2 trials

Cutaneous T-cell lymphoma2 trials

Primary Myelofibrosis2 trials

Prostate Cancer2 trials

HIV-12 trials

T-cell acute lymphoblastic leukemia1 trial

Mantle Cell Lymphoma1 trial

Surgery1 trial

Acute Lymphoblastic Leukemia1 trial

Sickle Cell Disease1 trial

Small Cell Lung Cancer1 trial

Adult T-Cell Leukemia/lymphoma1 trial

Hematologic Malignancies1 trial

Trial1 trial

Treatment1 trial

Acute Myeloblastic Leukaemia1 trial

Malignant Brain Tumors1 trial

Pancreatic Cancer1 trial

Myelofibrosis1 trial

HSCT1 trial

Relapsed/Refractory1 trial

Patients With Solid Tumors1 trial

Neuroendocrine Tumors1 trial

Gastric Cancer1 trial

Advanced1 trial

Combination Therapy1 trial

Solid Tumors1 trial

Renal Cell Cancer1 trial

Acute Myeloid Leukemia1 trial

Chronic Myelogenous Leukemia1 trial

Stereotactic Radiation1 trial

Liver Cancer1 trial

Essential Thrombocythemia1 trial

Myelodysplastic Syndromes1 trial

Metastatic Colorectal Cancer1 trial

Malignant Solid Tumors1 trial

Children1 trial

Esophageal Cancer1 trial

Colorectal Cancer1 trial

Unspecified2 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News